Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Pediatric Refractory Crohn's Disease
NCT03747718Phase 1Withdrawn
- Sponsor
- Stanford University
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Crohn's disease comparing FMT Maintenance with Placebo Maintenance (2 arms). Primary endpoint: Safety as assessed by Adverse events at 6 months. Planned start Dec 2022; status: withdrawn.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03747718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747718.